Appl. No. 08/466,554 Amdt. dated September 11, 2007 Reply to Office Action of May 23, 2007.

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

## Listing of Claims:

1-41. (Canceled)

42. (Previously Presented) A method for screening a compound to determine its ability to alter the amount of an A $\beta$  (x- $\geq$  41) peptide in a cerebral spinal fluid sample comprising:

measuring a first amount of one or more soluble A $\beta$  (x $\geq$  41) peptides in the cerebral spinal fluid sample of a non-human animal model that expresses amyloid- $\beta$  precursor protein (APP) in the brain and processes it to the one or more soluble A $\beta$  peptides;

administering the compound to the non-human animal model:

measuring a second amount of the one or more soluble  $A\beta$  peptides in the cerebral spinal fluid sample of the non-human animal model; and

comparing the first amount with the second amount,

the difference indicating whether the compound increases, decreases, or leaves unchanged the amount of soluble  $A\beta$  ( $x \ge 41$ ) in the cerebral spinal fluid sample, wherein the amount of  $A\beta$  ( $x \ge 41$ ) is measured by exposing the cerebral spinal fluid to an antibody or fragment thereof specific for an epitope of  $A\beta$  ( $x \ge 41$ ) but that does not cross react with an epitope of  $A\beta$  (x < 40).

43. (Currently Amended) The method of claim 42, wherein the non-human animal model is a transgenic rodent model of Alzheimer's disease. Appl. No. 08/466,554 Amdt. dated September 11, 2007 Reply to Office Action of May 23, 2007.

- 44. (Currently Amended) The method of claim 43, wherein the <u>transgenic</u> rodent model is a mouse model.
- 45. (Previously Presented) The method of claim 42, wherein the non-human animal model is a transgenic rodent model having an expression cassette that drives the expression of a sequence which encodes the Swedish mutation of an amyloid precursor protein (APP) gene.

46-47. (Canceled)

48. (Currently Amended) The method of claim 42, wherein the antibody [of]  $\underline{or}$  fragment thereof binds to A $\beta$  (x-42).

49-50. (Canceled)

- 51. (Previously Presented) The method of claim 42, wherein antibody or fragment thereof is an antibody recognizing an epitope on  $A\beta$  having amino acid residues 33-42.
- 52. (Previously Presented) The method of claim 51, wherein the antibody or fragment thereof is an antibody that will bind to A $\beta$  (x- $\geq$  41).
  - 53. (Canceled)
- 54. (Previously Presented) The method of claim 51, wherein the antibody or fragment thereof is an antibody that will bind to A $\beta$  (x- $\geq$  43).